Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Intragel
- Development stage
- Phase 3
- Lead developer
- IBSA
- Administration
- Intra-articular Injection
01
Overview
Intragel is a hyaluronic acid (HA) formulation designed for viscosupplementation, primarily used in the treatment of osteoarthritis. It is administered via intra-articular injection to alleviate pain and enhance joint function. The formulation contains 16mg of hyaluronic acid per 2cc, with an average molecular weight ranging from 800 to 1200 kiloDaltons. It works by restoring the elastoviscosity of the synovial fluid, thereby improving joint lubrication, shock absorption, and providing anti-inflammatory and analgesic effects. Intragel is developed and manufactured by IBSA.
- Brand names
- IntragelSinovialYaral
- Other names
- sodium hyaluronatehyaluronic acid
02
Targets
CD44 (CD44 antigen)ICAM1 (Intercellular Adhesion Molecule 1)RHAMM (Hyaluronan-mediated motility receptor)
Beyond the preview
Go deeper on Intragel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Intragel.